PHARMACY BENEFACT

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

Temporary benefits added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Teva-Spironolactone 25 mg Tablet (DIN 00613215) manufactured by Teva Canada Limited and Mint-Spironolactone 25 mg Tablet (DIN 02488140) manufactured by Mint Pharmaceuticals Inc., Jamp Spironolactone 25 mg Tablet (DIN 02518821) manufactured by Jamp Pharma Corporation will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **September 13, 2022**.

As of **September 13, 2022**, all claims for Jamp Spironolactone 25 mg Tablet (DIN 02518821) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

Due to the unavailability of Mint-Spironolactone 100 mg Tablet (DIN 02488159) manufactured by Mint Pharmaceuticals Inc. and Teva-Spironolactone 100 mg Tablet (DIN 00613223) manufactured by Teva Canada Limited, Jamp Spironolactone 100 mg Tablet (DIN 02518848) manufactured by Jamp Pharma Corporation will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **October 10, 2022**.

As of **October 10, 2022**, all claims for Jamp Spironolactone 100 mg Tablet (DIN 02518848) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

Due to the unavailability of Acetylcysteine 20% Inhalation Solution (DIN 02243098) manufactured by Sandoz Canada Inc., Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) manufactured by Hikma Canada Limited will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **October 14, 2022**.

As of **October 6, 2022**, all claims for Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

Temporary benefit added to the *Human Services Drug Benefit Supplement (HSDBS)*

Due to the unavailability of Salinex 0.9% Nasal Solution (NPN 80024901) manufactured by Exzell Pharma, Salinex 9 mg/ml Nasal Spray (NPN 80024381) manufactured by Exzell Pharma will be considered as a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*.

As of **October 12, 2022**, all claims for Salinex 9 mg/ml Nasal Spray (NPN 80024381) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

continued next page





continued from previous page

Product supply shortages addressed for the *Alberta Drug Benefit List* (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Dabigatran 110 mg Capsule (DIN 02468905) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **November 14, 2022**. The following grouping was removed from the Critical Supply Product List on **October 13, 2022**.

DABIGATRAN ETEXILATE

110 MG CAPSULE

00002468905	APO-DABIGATRAN	APX	\$ 1.2540
00002312441	PRADAXA	BOE	\$ 1.7309

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Dabigatran 150 mg Capsule (DIN 02468913) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **November 14, 2022**. The following grouping was removed from the Critical Supply Product List on **October 13, 2022**.

DABIGATRAN ETEXILATE

150 MG CAPSULE

00002468913	APO-DABIGATRAN	APX	\$ 1.2540
00002358808	PRADAXA	BOE	\$ 1.7309

Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortages of Apo-Amitriptyline 25 mg Tablet (DIN 02403145) manufactured by Apotex Inc. and Elavil 25 mg Tablet (DIN 00335061) manufactured by AA Pharma Inc., Mar-Amitriptyline 25 mg Tablet (DIN 02429888) manufactured by Marcan Pharmaceuticals Inc and pms-Amitriptyline 25 mg Tablet (DIN 00654515) manufactured by Pharmascience Inc. were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Apotex Inc. and AA Pharma Inc., have advised Alberta Blue Cross that the shortages for Apo-Amitriptyline 25 mg Tablet (DIN 02403145) and Elavil 25 mg Tablet (DIN 00335061), respectively, have been resolved.

As a result, Mar-Amitriptyline 25 mg Tablet (DIN 02429888) and pms-Amitriptyline 25 mg Tablet (DIN 00654515) will no longer be considered temporary benefits for the *ADBL* after **November 18, 2022**. The above grouping was removed from the Critical Supply Product List on **October 19, 2022**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free) Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



